TRACEBACK:对历史输卵管卵巢癌患者进行遗传风险基因检测作为家庭成员癌症预防策略
该先导研究从研究队列、亲属确认和妇科肿瘤门诊确定已故先证者,用档案组织或储存血液对10个风险相关基因进行panel测序,在787例中84例(11%)检出85个致病性变异。60例有可通知对象的已故先证者中39例(65%)家属收到书面结果通知,85%完成电话随访,多数家庭获得新信息并接受遗传服务转诊。
要点
- 在787例已故输卵管卵巢癌先证者中,84例(11%)检出致病性变异。
- 60例有可通知对象的先证者中,39例(65%)家属获书面通知,85%完成电话随访。
- 多数家庭(29/33,88%)获得新遗传信息,66%(19/29)接受遗传服务转诊。
核心结论
- 研究克服伦理和后勤挑战,证明对既往未检测的已故输卵管卵巢癌先证者进行回顾性遗传检测以发现致病性变异是可行的。
- 了解家庭成员接受或拒绝转诊的原因对指导未来TRACEBACK项目很重要。
研究设计与样本
- 先导研究,从研究队列、亲属确认和妇科肿瘤门诊确定已故先证者。
- 从档案组织或储存血液提取DNA,对10个风险相关基因进行panel测序。
- 通过临床记录确定的已故先证者检测在知情同意豁免下进行。
主要发现
- 在787例先证者中84例(11%)检出85个致病性变异。
- 84例检出致病性变异的先证者中60例(71%)有可通知对象。
- 60例有可通知对象的已故先证者中39例(65%)家属收到书面结果通知,其中85%(33/39)完成电话随访。
- 少数家庭(n=4)已知道该致病性变异。
- 对多数家庭(29/33,88%)而言遗传结果提供了新信息,大多数病例(66%,19/29)接受遗传服务转诊。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Tubo-ovarian cancer (TOC) is a sentinel cancer for BRCA1 and BRCA2 pathogenic variants (PVs). Identification of a PV in the first member of a family at increased genetic risk (the proband) provides opportunities for cancer prevention in other at-risk family members. Although Australian testing rates are now high, PVs in patients with TOC whose diagnosis predated revised testing guidelines might have been missed. We assessed the feasibility of detecting PVs in this population to enable genetic risk reduction in relatives. PATIENTS AND METHODS: In this pilot study, deceased probands were ascertained from research cohort studies, identification by a relative, and gynecologic oncology clinics. DNA was extracted from archival tissue or stored blood for panel sequencing of 10 risk-associated genes. Testing of deceased probands ascertained through clinic records was performed with a consent waiver. RESULTS: We identified 85 PVs in 84 of 787 (11%) probands. Familial contacts of 39 of 60 (65%) deceased probands with an identified recipient (60 of 84; 71%) have received a written notification of results, with follow-up verbal contact made in 85% (33 of 39). A minority of families (n = 4) were already aware of the PV. For many (29 of 33; 88%), the genetic result provided new information and referral to a genetic service was accepted in most cases (66%; 19 of 29). Those who declined referral (4 of 29) were all male next of kin whose family member had died more than 10 years before. CONCLUSION: We overcame ethical and logistic challenges to demonstrate that retrospective genetic testing to identify PVs in previously untested deceased probands with TOC is feasible. Understanding reasons for a family member's decision to accept or decline a referral will be important for guiding future TRACEBACK projects.
引用
- Delahunty R, Nguyen L, Craig S, et al. TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members. J Clin Oncol. 2022. PMID: 35263119. doi:10.1200/JCO.21.02108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。